罗格列酮相关心血管事件概述

被引：4

作者：

王梦然 ^{[1
]}

李敏 ^{[1
]}

机构：

[1] 首都医科大学附属北京友谊医院综合科

来源：

药物不良反应杂志 | 2009年 / 01期

关键词：

罗格列酮; 心血管事件; 不良反应;

D O I：

暂无

中图分类号：

R977.15 [];

学科分类号：

1007 ;

摘要：

罗格列酮为噻唑烷二酮类口服降糖药,能改善胰岛素敏感性,用于治疗2型糖尿病。近年,罗格列酮的心血管风险受到人们关注。一项荟萃分析显示:罗格列酮组与对照组比较,心肌梗死的优势比(OR)为1.43,[95%可信区间(CI)1.03～1.98,P=0.03];心血管性死亡OR为1.64,(95%CI0.98～2.74,P=0.06),表明罗格列酮与心肌梗死及心血管性死亡有关联。然而,最近RECORD中期研究显示:罗格列酮组心肌梗死49例,对照组40例(P=0.34),而两组的充血性心力衰竭分别为47例和22例(P=0.003),表明罗格列酮不增加心肌梗死和心血管性死亡风险,但可使充血性心力衰竭风险增加。另外,FDA2008年发布了有关罗格列酮的用药指南和处方信息,罗格列酮禁用于严重心力衰竭患者。因此,使用罗格列酮时应权衡利弊,并应个体化用药。

引用

页码：31 / 34

页数：4

共 18 条

[1] 噻唑烷二酮类药物对心血管相关危险因素的影响 [J].

郑仁东 ;

任安 .

国外医学(老年医学分册), 2008, (02) :71-75

[2] NF-κBp65/IL-1β在心肌梗死大鼠心室重塑中的表达及罗格列酮对其的影响 [J].

汪涛 ;

李恩 ;

刘宗芳 .

华南国防医学杂志, 2008, (02) :56-59

[3]

Diabetes[P]. 英国专利:GB201117172D0,2011-11-16

[4]

In vivo Myocardial protection from ischemia/reperfusion injury by the Peroxisome Proliferator-activated receptor-γ agonist rosiglitazone. Tian-li Yue, PhD,Jun Chen, MS,Weike Bao et al. Circulation . 2001

[5]

Effects of glitazones on blood pressure and vascular structure in mesenteric resistance ar-teries and basilar artery from genetically hypertensive rats. Ledingham JM,Laverty R. Clinical and Experimental Pharmacology and Physiology . 2005

[6]

A randomized trial of the effects of rosiglitazone and metformin on inflam-mation and subclinical atherosclerosis in patients with type2diabetes. Stocker DJ,Taylor AJ,Langley RWet al. American Heart Journal . 2007

[7]

Ambulatory blood pressure reduction after rosiglitazone treat ment in patients withtype2diabetes and hypertension correlates withinsulin sensi-tivity increase. Sarafidis PA,Lasaridis AN,Nilsson PM,et al. Journal of Hypertension . 2004

[8] A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes [J].

Stocker, Derek J. ;

Taylor, Allen J. ;

Langley, Roy W. ;

Jezior, Mattliew R. ;

Vigersky, Robert A. .

AMERICAN HEART JOURNAL, 2007, 153 (03) :445.e1-445.e6

[9]

PPAR-gamma activation inhibits angiotensinⅡsynthesis,apoptosis,and proliferation of mesangial cells from spontaneously hypertensive rats. Efrati S,berman S,Ilgiyeav E,et al. Nephron Experimental Nephrology . 2007

[10]

Thiazolidinedio-nes and risk for atherosclerosis:pleiotropic effects of PPAR gamma agonism. Patel CB,De Lemos JA,Wyne KLet al. Diab Vasc Dis Res . 2006

← 1 2 →